

share
9-Hydroxyolivacine CAS NO 70173-18-1
Unit Price:
CAS No.:70173-18-1
Grade:Pharmacy Grade
Content:99.9%
Brand:Customizable
Packaging:Customizable
Description
9-Hydroxyolivacine is a synthetic derivative of the olivacine alkaloid family, recognized for its complex heterocyclic structure. This compound is of significant interest in advanced pharmaceutical research and development due to its potential as a key synthetic intermediate or a lead compound for biological activity studies. It is primarily utilized by research institutions and pharmaceutical companies engaged in the development of novel therapeutic agents, particularly in the fields of oncology and antimicrobial research.
Application
- Pharmaceutical Intermediate: Serves as a critical building block in the synthesis of more complex alkaloid derivatives for drug discovery programs.
- Oncology Research: Investigated as a potential lead compound or molecular scaffold for developing new anticancer agents due to its structural similarity to bioactive natural products.
- Biochemical Research: Used in in vitro studies to explore interactions with biological targets such as DNA topoisomerases or specific cellular receptors.
- Reference Standard: Employed as an analytical standard in high-performance liquid chromatography (HPLC) or mass spectrometry for quality control and method development in research settings.
- Chemical Synthesis: Acts as a versatile starting material for medicinal chemists to create novel chemical libraries for high-throughput screening.
Basic Information
| Product Name | 9-Hydroxyolivacine |
| CAS No. | 70173-18-1 |
| Molecular Formula | C17H14N2O |
| Molecular Weight | 262.31 g/mol |
| Synonyms | 9-Hydroxyolivacine; 9-Olivacinol; 5H-Pyrido[4,3-b]carbazol-9-ol; 9-Hydroxy-5H-pyrido[4,3-b]carbazole; Olivacine-9-ol |
| EINECS | Contact for details |
Quality Control
Our 9-Hydroxyolivacine is produced under strict quality management protocols to ensure batch-to-batch consistency and high purity suitable for research applications. Each lot is accompanied by a comprehensive Certificate of Analysis (COA) detailing identity, purity, and impurity profiles. We adhere to relevant Good Manufacturing Practice (GMP) principles for active pharmaceutical ingredients (APIs) where applicable.
Storage
Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). The product is light-sensitive and should be handled under appropriate conditions to prevent degradation.
Specification
| Item | Specification |
|---|---|
| Appearance | Yellow to brown powder |
| Identification (IR) | Conforms to reference spectrum |
| Purity (HPLC) | ≥ 95.0% |
| Loss on Drying | ≤ 2.0% |
| Residue on Ignition | ≤ 0.5% |
Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.
Hot Related Products


Rutaecarpine CAS NO 84-26-4


1,7-Dimethylxanthine CAS NO 611-59-6


Capsaicin CAS NO 404-86-4


Catharanthine CAS NO 2468-21-5


Muscimol Hydrate CAS NO 18174-72-6


Muscimol CAS NO 2763-96-4


Mesembrine CAS NO 468-53-1


Dihydroberberine CAS NO 483-15-8


6-Methoxyharmalan CAS NO 3589-73-9


Nicotine CAS NO 54-11-5


Quinine Hydrochloride Dihydrate CAS NO 6119-47-7


Arecoline CAS NO 63-75-2


Tetrahydropapaverine Hydrochloride CAS NO 6429-04-5


L-Hyoscyamine CAS NO 101-31-5


14,17-Dihydro-3-Methoxy-16(15H)-Oxaerythrinan-15-One (3Beta)- CAS NO 115-36-6


Sinomenine CAS NO 115-53-7


Benzog-1,3-Benzodioxolo5,6-Aquinolizinium, 5,6-Dihydro-9,10-Dimethoxy-, Hydroxide CAS NO 117-74-8


Cinchonine CAS NO 118-10-5


Cevine CAS NO 124-98-1


Vomicine CAS NO 125-15-5
Why choose US
Trusted Manufacturer
With our own production facilities, we ensure consistent quality, reliable supply, and full traceability.
Rigorous Quality Assurance
Each batch undergoes strict QC, accompanied by COA, MSDS, and full compliance with international standards.
Advanced R&D Expertise
Our in-house lab drives process innovation, new product development, and tailored synthesis solutions.






